nanOss Strata™ is designed to more closely mimic the structure of human bone, increase graft surface area, improve osteoconductivity and enhance stimulation of cellular activity.
BELGRADE, Montana, Dec. 11, 2025 /PRNewswire/ — Xtant Medical Holdings, Inc. (NYSE American:
nanOss Strata is manufactured from hydroxycarbonapatite (HCA), a material with greater solubility than traditional hydroxyapatite (HA), the most widely used synthetic material. Greater solubility may improve the bioactivity of the graft, allowing for better integration and remodeling with the surrounding bone tissue during the healing process. The HCA nanocrystalline structure used in nanOss Strata is designed to closely mimic human bone and increase surface area for improved osteoconductivity and stimulation of patient cell activity on the graft surface after implantation.
Strata is available in preformed compression-resistant strips and pre-hydrated moldable grafts. Both options are sterile, highly moldable, and rapidly absorb blood and other biological fluids.
Sean Browne, President and CEO of Xtant Medical, said: “By building on the clinical success of our nanOss products, Strata further demonstrates our commitment to innovation in regenerative medicine. We are excited to introduce this new technology to help our surgeon customers improve surgical outcomes for their patients.”
nanOss Strata is now accessible through Xtant Medical’s national distribution network.
About Xtant Medical Holdings, Inc.
Xtant Medical’s mission to honor the gift of donation so that our patients can live the fullest and most complete lives possible is the driving force behind our company. Xtant Medical Holdings, Inc. (www.xtantmedical.com) is a global medical technology company focused on the design, development and commercialization of a comprehensive portfolio of orthobiological products serving the sports medicine, chronic and surgical wound care markets, as well as spinal implant systems. Xtant’s staff is dedicated and talented and operates with the highest integrity to serve our customers.
The symbols ™ and ® denote trademarks and registered trademarks of Xtant Medical Holdings, Inc. or its affiliates, registered as indicated in the United States and other countries. All other trademarks and trade names mentioned in this release are the property of their respective owners.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements that are predictive in nature, that depend on or refer to future events or conditions, or that contain words such as “intends,” “expects,” “anticipates,” “plans,” “believes,” “estimates,” “continues,” “future,” “will,” “potential,” similar or negative expressions. thereof, and the use of future dates. Forward-looking statements in this release include the company’s expectations regarding the benefits and performance of nanOss Strata™ and its potential to improve outcomes for patients using nanOss Strata™. The Company cautions that its forward-looking statements by their nature involve risks and uncertainties, and actual results may differ materially depending on a variety of important factors, including, but not limited to: the ability of nanOss Strata™ and other new products to gain market acceptance, perform as designed and intended, and meet the needs of surgeons and patients; the ability of the Company and its sales personnel and distributors to successfully sell nanOss Strata™; the Company’s ability to successfully manufacture nanOss Strata™ and in the quantities necessary to meet demand; the Company’s ability to continue to innovate, develop and introduce new products and the success of those products; the performance and success of the Company’s fully vertically integrated structure; the Company’s ability to recruit and retain new and existing independent distributors, agents and qualified personnel and its dependence on key independent agents for a significant portion of its revenues; the Company’s future operating and financial performance and its ability to increase or maintain revenues; and other risk factors, including in particular those associated with the launch of new products, contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024 filed with the Securities and Exchange Commission (SEC) on March 6, 2025 and subsequent filings with the SEC by the Company, including, but not limited to, its most recent Quarterly Report on Form 10-Q for the quarterly period ended December 30, September 2025 filed with the SEC in November. January 10, 2025. Investors are encouraged to read the company’s filings with the SEC, available at www.sec.gov, to discuss these and other risks and uncertainties. The Company undertakes no obligation to release publicly any revisions to any forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, except as required by law. All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by this cautionary statement.
SOURCE Xtant Medical Holdings, Inc.
